Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Davis, Kara L  [Clear All Filters]
2023
Sarno J, Domizi P, Liu Y, Merchant M, Pedersen CBligaard, Jedoui D, Jager A, Nolan GP, Gaipa G, Bendall SC, et al. Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia. Nat Commun. 2023;14(1):2935.
Pan F, Sarno J, Jeong J, Yang X, Jager A, Gruber TA, Davis KL, Cleary ML. Genome editing-induced t(4;11) chromosomal translocations model B cell precursor acute lymphoblastic leukemias with KMT2A-AFF1 fusion. J Clin Invest. 2023.
2022
Long AH, Morgenstern DA, Leruste A, Bourdeaut F, Davis KL. Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. Am Soc Clin Oncol Educ Book. 2022;42:1-14.
Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022.
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, de Moerloose B, Qayed M, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2022:JCO2200642.
2020
Lin CH, Kuehn HSun, Thauland TJ, Lee CM, De Ravin SSee, Malech HL, Keyes TJ, Jager A, Davis KL, Garcia-Lloret MI, et al. Progressive B Cell Loss in Revertant X-SCID. J Clin Immunol. 2020.
2019
Laetsch TW, Myers GDouglas, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, Buechner J, de Moerloose B, Davis KL, Nemecek E, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019.